Business Context and Reporting Period
This Form 8-K is a current report filed by AVROBIO, Inc. (noting a discrepancy in the request metadata which listed "Tectonic Therapeutic, Inc.") on October 19, 2020. The filing reports on corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial figures disclosed relate to director compensation:
- Annual Service Retainer: $39,000 for the new director.
- Committee Fee: $4,000 included in the retainer for the Science & Technology Committee.
- Stock Option Grant: Option to purchase 28,000 shares of common stock.
Material Changes
The primary material change reported is the increase in the size of the Board of Directors from seven to eight members. Gail M. Farfel, Ph.D. was appointed as a Class I director effective immediately, serving until the 2022 annual meeting. She was also appointed to the Science & Technology Committee.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies. It strictly addresses the appointment of a director and the associated compensatory arrangements. The company confirmed there are no undisclosed arrangements or related party transactions requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the correct registrant name is AVROBIO, Inc. (trading symbol: AVRO), as the request metadata incorrectly referenced Tectonic Therapeutic, Inc.
- Confirm the new board composition now includes eight directors, with Dr. Farfel serving as a Class I director.
- Note the specific compensation package: $39,000 annual retainer and a 28,000-share stock option grant.
- Review the attached press release (Exhibit 99.1) for additional context on Dr. Farfel's background and qualifications.